Cohen OC, Sharpley F, Gillmore JD, et al. - Researchers describe the outcomes of management with ixazomib + lenalidomide + dexamethasone (IRd) in patients with relapsed amyloid light-chain (AL) amyloidosis (n = 40). On an intention-to-treat basis, they evaluated haematological responses at three months: complete response (CR) – 8 (20·5%), very good partial response (VGPR) – 8 (20·5%), partial response (PR) – 7 (17·9%) and no response (NR) – 16 (41·0%). Best responses reported were as follows: CR – 10 (25·6%), VGPR – 8 (20·5%), PR – 7 (17·9%), NR – 14 (35·9%). The estimated median progession-free survival was 17·0 months, which improved to 28·8 months in those attaining CR/VGPR. The median overall survival was estimated to be 29·1 months. Overall, IRd was identified as an oral treatment option that has a manageable toxicity profile and induced deep responses in 47% of patients with relapsed AL amyloidosis.